Clinical Trial Update: First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia [Phase 1, Phase 2]

View source ↗

Summary

First-in-human study of ziftomenib in relapsed or refractory acute myeloid leukemia is underway in Phase 1/Phase 2 trials and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Ziftomenib (ziftomenib)

Snippet

Sponsor: Kura Oncology, Inc. | Conditions: Advanced Malignant Neoplasm, Acute Myeloid Leukemia | Phase 1, Phase 2 | Status: RECRUITING